Kepler Capital Markets set a €66.00 ($76.74) price objective on Stratec Biomedical AG (ETR:SBS) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the stock.

A number of other research analysts have also commented on SBS. Oddo Securities set a €58.00 ($67.44) price target on Stratec Biomedical AG and gave the company a neutral rating in a research report on Monday, July 24th. Berenberg Bank set a €59.00 ($68.60) price target on Stratec Biomedical AG and gave the company a neutral rating in a research report on Tuesday, July 25th. Finally, Warburg Research set a €62.00 ($72.09) price target on Stratec Biomedical AG and gave the company a buy rating in a research report on Tuesday, July 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Stratec Biomedical AG has a consensus rating of Hold and an average target price of €60.00 ($69.77).

Shares of Stratec Biomedical AG (ETR SBS) opened at 52.206 on Wednesday. Stratec Biomedical AG has a one year low of €41.45 and a one year high of €63.18. The firm has a 50-day moving average price of €57.73 and a 200-day moving average price of €54.04. The company has a market capitalization of €620.62 million and a P/E ratio of 32.246.

COPYRIGHT VIOLATION WARNING: “Kepler Capital Markets Analysts Give Stratec Biomedical AG (SBS) a €66.00 Price Target” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/kepler-capital-markets-analysts-give-stratec-biomedical-ag-sbs-a-66-00-price-target/1461944.html.

About Stratec Biomedical AG

Stratec Biomedical AG (Stratec) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with Analyst Ratings Network's FREE daily email newsletter.